November 30, 2018 8:13am
News: Editas Medicine (EDIT had closed +$0.74) the FDA has accepted an IND application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). With the IND acceptance, EDIT has earned a $25 M milestone payment from Allergan as part of the alliance between the companies to discover and develop experimental ocular medicines - BUY
I answer one question, in which company should investors put, keep and commit their money! Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector.
Today is the LAST of the FREE reads, even on alternating days - I shown investors and traders a path so - it's time to reward my hard work and long hours.
U.S. stock index futures are falling ...
Reiterating my mantra, “Skim if you can trim, buy if it will fly and sell if compelled!”
Dow futures are DOWN -0.49% (-125 points) and NASDAQ futures are DOWN -0.39% (-27 points)
Dow set to fall 100 points as high-stakes G-20 puts trade in spotlight
European stocks hovered around the flat line, as key leaders congregated for a major event in Argentina.
Asia Pacific markets traded mixed as investors waited for a highly-anticipated meeting between President Donald Trump and his Chinese counterpart Xi Jinping at the G-20 summit in Argentina.
Data docket: Chicago PMI (purchasing managers' index) and U.S. PMI manufacturing index figures are due to be released at 9:45 a.m. ET.
- The iShares Nasdaq Biotechnology (IBB) is NOT indicating
- The SPDR S&P Biotech ETF (XBI) is NOT indicating
- The Health Care Select Sector SPDR ETF (XLV) is indicating a NEGATIVE -0.07% DOWNSIDE
- The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.4% DOWNSIDE
Downside oriented futures took their cue from international markets on Friday. Equities in Europe and Asia were both seen mixed as attention centered on the G-20 summit in Buenos Aires.
Last night’s closing bell remarks, “an expected black and white session after yesterday’s up session. We are continually vexed about volatility as related to volume especially when markets are jittery.”
Last night’s percentage (%) indicators:
- Review the range of the 20 upside from +0.53% (AXGN) to +12.64% (CLBS +$0.56) while the 24 downside ranged from -0.08% (SGMO) to -12.06% (HSGX) with a 1 flat close (BSTG – the usual favorite).
- 1 out of 20 upside had higher (than the 3 month average) volume
- 6 out of 24 downside experienced greater volume (than the 3 month average).
In 21 sessions in November – there were 1 holiday, 9 positive closes, 1 neutral and 10 negative closes
- In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
- In 19 sessions in September – there were 10 negative closes and 9 positive sessions;
- In 21 August sessions – 6 had negative and 15 had positive closes
Companies in my headlights – It’s your decision; I provide an idea and context:
I am happy to see November – the month of volatility and low volume ENDS yet; it scares me about what is ahead in December.
De-risking is the new buzzword for selling even after the alternating share pricing – equities are NOT cheap ENOUGH for a run to buy.
Don't try to catch ANY "falling knives"!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.